Recombinant human metapneumovirus and its use
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsPeter L. Collins, Stephane Biacchesi, Ursula Buchholz, Mario H. Skiadopoulos, Brian R. Murphy
Life of this patent
Estimating the term…
Abstract
Recombinant HMPV (rHMPV) and related immunogenic compositions and methods are provided. The rHMPVs, including chimeric and chimeric HMPV vectors viruses, provided according to the current disclosure are infectious and attenuated in permissive mammalian subjects, including humans. The rHMPVs are useful in immunogenic compositions for eliciting an immune response against HPIV, against one or more non-HMPV pathogens, or against a HMPV and a non-HMPV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant HMPV genome or antigenome.
Claims8
An attenuated, replication competent recombinant human metapneumovirus (rHMPV), comprising a recombinant HMPV genome or antigenome of SEQ ID NO:
- 1 or SEQ ID NO:
- 2, comprising one or more attenuating nucleotide modifications including a partial or complete deletion of the rHMPV M2-2 ORF or one or more nucleotide substitutions that ablates expression of the rHMPV M2-2 ORF, and a major nucleocapsid (N) protein, a nucleocapsid phosphoprotein (P), and a large polymerase protein (L) of a HMPV.
Dependencies are inferred from the claim text.